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Abstract
Background: 2,3-Butanedione monoxime (BDM) has been widely used as a non-muscle myosin
inhibitor to investigate the role of non-muscle myosinII in the process of actin retrograde flow and
other actin cytoskeletal processes. Recent reports show that BDM does not inhibit any non-muscle
myosins so far tested, including nm-myosinII, prompting the question, how were these process
affected in BDM studies?
Results: We have found that treatment of mammalian cells with BDM for only 1 min blocks actin
incorporation at the leading edge in a permeabilized cell system. We show that inhibition of actin
incorporation occurs through de-localization of leading edge proteins involved in actin
polymerization – the Arp2/3 complex, WAVE, and VASP – that de-localize concomitantly with the
leading edge actin network.
Conclusion: De-localization of actin leading edge components by BDM treatment is a newly
described effect of this compound. It may explain many of the results previously ascribed to
inhibition of non-muscle myosinII by BDM, particularly in studies of leading edge dynamics. Though
this effect of BDM is intriguing, future studies probing actin dynamics at the leading edge should use
more potent and specific inhibitors.
Background
The actin cytoskeleton is a dynamic system composed of
actin filaments, proteins that regulate filament dynamics,
and proteins that remodel and make use of the cytoskele-
tal network. An important aspect of actin cytoskeletal
research has been the use of small molecules that affect
actin dynamics and proteins that act on the cytoskeleton
[1]. 2,3-butanedione monoxime (BDM) is a small mole-
cule that inhibits the ATPase activity of muscle myosinII
and reduces the force generated by this motor protein
[2,3]. BDM was introduced to the cell biology community
as a millimolar inhibitor of multiple non-muscle myosins
with greatest potency in inhibiting non-muscle myosinII
[4]. It was subsequently used, in concert with other
approaches, to study nm-myosinII function in a variety of
biological processes [5–8]. BDM was recently shown not
to inhibit any non-muscle myosins so far tested, leaving
the question of how it affects cells unanswered [9,10].
One process inhibited by BDM is the centripetal flow of
actin from the leading edge into the cell body, known as
retrograde flow [11,12]. Retrograde flow is thought to be
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driven by a "push-pull" mechanism of polymerization of
actin at the leading edge of the cell and contractile activity
of myosin motor proteins [13,14]. Formation of new actin
filaments is predominantly mediated by the nucleation
activity of the Arp2/3 complex [15]. Members of the
WASP/WAVE family of proteins, among others, stimulate
and regulate the Arp2/3 complex for spatial and temporal
control of filament nucleation [15]. Localization of these
proteins to the leading edge, though not completely
understood, is probably mediated through their interac-
tions with the actin cytoskeleton itself and membrane-
associated binding partners [15,16].
Inhibition of retrograde flow by BDM has been used as
evidence for the role of nm-myosins in retrograde flow
[12]. Though not explicitly stated, the localization and
importance of nm-myosinII in multiple cell types, and the
fact that BDM was thought to have greatest potency in
inhibiting nm-myosinII has led most to look at BDM's
effect on retrograde flow as a result of inhibiting this pro-
tein. [11,17,18]. A role for nm-myosinII may exist, given
its localization and that other perturbations that affect
myosin function – myosin S1 microinjection, ML-7 treat-
ment, and expression of dominant negative nm-myosinII
constructs and have similar effects to BDM treatment
[5,7,12]. However, a study in chick dorsal root ganglia
neurons where nm-myosinII was inactivated using
chromophore assisted laser inactivation saw no effect on
retrograde flow rates [19]. We know now that BDM does
not in fact inhibit nm-myosinII. So, is this effect that we
see with BDM mediated by other proteins involved in ret-
rograde flow? And what can this tell us about the mecha-
nism of retrograde flow? How similar is this process to
other actin mediated processes that use these same pro-
teins, such as Listeria motility? BDM has a clear effect on
a number of cell biological processes. Understanding how
these effects are mediated can help us learn from BDM
and reinterpret experiments that made use of it, while
working to find new and better inhibitors.
Results
BDM inhibits actin incorporation in mammalian cells
BDM has been reported to not inhibit nm-myosinII
ATPase activity [9]. We show data [Figure 1A] that sup-
ports this report. The ATPase activity of platelet nm-
myosinII S1 fragment, is not inhibited by BDM while the
inhibitor, blebbistatin, decreases ATPase activity by more
than 90%. The stimulation of ATPase activity by BDM
[Figure 1A] is similar to a ~2 fold increase seen previously
(A. Straight personal communication).
Though BDM does not inhibit nm-myosinII, in permeabi-
lized yeast (S. cerviseae) BDM has been shown to decrease
incorporation of exogenous actin into the cytoskeleton
[20]. This process of actin incorporation requires proteins
involved in actin filament formation and proteins that
may localize a nucleation complex [20,21]. To determine
if BDM has a similar effect on actin incorporation in
Figure 1
BDM treatment inhibits actin incorpolration in a per-
meabilized cell system. (A) BDM does not inhibit platelet 
myosinII S1 ATPase activity. (B) Spreading Swiss3T3 cells 
were treated with a media control, BDM, or cytochalasin D 
for 1 minute prior to permeabilization and incubation with 
rhodamine-labeled actin. BDM treatment blocks actin incor-
poration at the leading edge while control and cyto D treat-
ment have no effect. Bar, 50 um.
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mammalian cells, and if so an effect on actin nucleation,
spreading Swiss3T3 cells were treated briefly with a media
control or 15 mM BDM and then permeabilized with the
detergent saponin in the presence of fluorescently labeled
actin. The cells were then fixed and incorporation of exog-
enous actin was determined by fluorescence microscopy
[22]. Control cells show fluorescent incorporation at the
periphery, or leading edge, of the cell [Figure 1B]. Treat-
ment of cells with 15 mM BDM for one minute blocked
incorporation at the leading edge, as seen by the lack of
fluorescence intensity, without significant effects on cell
morphology [Figure 1B]. Cells that remained flat and were
not disrupted by the permeabilization process were
counted, and more than 75% (3 trials) showed decreased
fluorescence similar to that seen in Figure 1B (cells that
showed significant perturbation by the permeabilization
process did not show greater actin incorporation). Incuba-
tion in BDM for longer than 1 minute caused more pro-
nounced morphological change upon permeabilization,
and one-minute treatment was used for subsequent
experiments.
As a control, cytochalasin D, a small molecule that inhib-
its actin dynamics by capping the growing ends of actin
filaments, was added to cells. If added prior to permeabi-
lization but not during, exogenous actin was still able to
incorporate into permeabilized cells and fluorescence
incorporation was high, similar to control cells [Figure 1].
As cytochalasin D has a high affinity (50 nM) for the
growing ends of actin filaments, this treatment should
inhibit polymerization of existing filaments but should
not block new filament formation [23]. Thus the actin
incorporated most likely reflects nucleation of new fila-
ments, as previously discussed [24]. As expected, cells
treated with cytochalasin D during permeabilization
showed no actin incorporation (data not shown).
To determine if BDM was affecting actin dynamics
directly, we assayed its ability to inhibit in vitro actin
assembly. No effect was seen on the polymerization of
actin alone or as stimulated by VCA-activated Arp2/3
complex, using a pyrene-actin polymerization assay (data
not shown). This result was supported by the observation
that Listeria monocytogenes continue to move intracellu-
larly, as described below.
Arp3 is no longer localized at the leading edge with BDM 
treatment
Since actin incorporation is not due to elongation of exist-
ing filaments and BDM does not affect pure actin dynam-
ics in vitro, we examined the localization of Arp3, a
subunit of the actin nucleation Arp2/3 complex. In
spreading Swiss3T3 cells and spread BS-C-1 cells, Arp3
localized to the leading edge of the cell. However, after
treatment with 20 mM BDM for one minute, localization
Figure 2
Arp3 is de-localized with BDM treatment. (A) BS-C-1 
cells stained for Arp3 and actin after 1 minute of treatment 
with a media control, BDM, cytochalasin D, or both BDM 
and cytochalasin D. BDM treatment leads to de-localization 
of Arp3 and loss of the brightly stained leading edge actin 
network. Arp3 is not de-localized with cytochalasin D treat-
ment or a combination of cyto D and BDM, suggesting that 
actin dynamics may be required for de-localization. The per-
centage of cells with the phenotype pictured is noted for 
each treatment (n =100 cells). Bar, 50 um. (B) Higher magni-
fication of control and two BDM treated fields show actin 
and Arp3 staining. Actin at the leading edge of control cells 
(arrow) is denser, suggestive of a well-organized network, 
and has fewer bundled projections as compared to BDM 
treatment. Bar, 20 um.
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was lost in over 90% of the cells [Figure 2A]. Results for
BS-C-1 and Swiss3T3 cells lines were equivalent and the
results from BS-C-1 cells are shown here, as they are used
in subsequent time-lapse experiments. Consistent with
the inhibition of actin polymerization in the permeabi-
lized cell assay, cells treated with BDM do not show a
brightly staining actin network at the leading edge [Figure
2A,2B]. Titration of BDM down to 10 mM showed the
same loss of localization; however, 2 minutes of treatment
was required to see equivalent loss (data not shown). To
control for possible osmotic effects of BDM treatment, we
treated cells with 20 mM urea, and as with a media con-
trol, more than 90% of the cells showed localization of
Arp3 at the leading edge.
To determine if inhibition of actin dynamics alone was
sufficient for the loss of Arp3 localization, we treated cells
with cytochalasin D and examined the localization of
Arp3. Within one minute at 1 uM cytochalasin D, cell ruf-
fling ceased, yet Arp3 remained at the leading edge [Figure
2A]. In fact, Arp3 staining at the leading edge was consist-
ently higher. Combining cytochalasin D and BDM, we
saw localization equivalent to or greater than no drug
treatment [Figure 2A]. Thus, actin dynamics may be
required for the loss of Arp3 at the leading edge upon
BDM treatment.
As mentioned, Listeria infected cells were used to confirm
that BDM does not directly affect actin dynamics. Listeria
exploit cellular – actin polymerization and organization –
proteins to move intracellularly. We found that 20 mM
BDM does not affect movement of bacteria inside treated
cells [Figure 3A] consistent with a previous report [4].
Interestingly, localization of Arp3 in Listeria comet tails is
unaffected with BDM treatment [Figure 3B] though Arp3
localization at the leading edge of these cells is disrupted.
VASP and WAVE are no longer localized to the leading 
edge with BDM treatment
To ask whether the loss of leading edge localization was
specific to the Arp complex, we examined the localization
of VASP and WAVE1 with BDM treatment. Both VASP and
WAVE function in controlling actin dynamics at the lead-
ing edge – VASP is thought to promote filament elonga-
tion, and WAVE, actin nucleation [25,26]. Both VASP and
WAVE1 were de-localized from the leading edge after 1
min of BDM treatment [Figure 4]. Similar to Arp3, the
localization of these proteins was not disrupted by cytoch-
alasin D treatment, or by the combination of cytochalasin
D and BDM [Figure 4].
Dynamics of the loss of Arp-3 localization
Two possible mechanisms for Arp2/3 complex de-locali-
zation were considered: Arp2/3 could move back from the
leading edge with retrograde flow of actin and then be lost
from the filaments, or it could simply diffuse from the
leading edge. To determine the dynamics of loss of Arp2/
3 complex localization, we generated a stable cell line
expressing Arp3-GFP. After BDM treatment, we observed a
uniform decrease in fluorescence suggestive of dissocia-
tion and diffusion of Arp3, rather than de-localization
Figure 3
Movement of Listeria monocytogenes and Arp3 locali-
zation in the actin comet tail is not disrupted with 
BDM. (A) A Listeria bacterium (boxed) continues to move 
with a phase dense actin tail after BDM addition at 0s. Inhibi-
tion of cell ruffling can be seen at 120s, the outline of the cell 
boundary at 0s is marked by a dotted line. (B) Localization of 
Arp3 in Listeria comet tails shows no discernible difference 
between control and BDM treatment. Note the lack of local-
ization at the leading edge of the BDM treated cells. 
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Figure 4
VASP and WAVE1 are de-localized with BDM treatment. BS-C-1 cells stained for VASP or WAVE1 after treatment 
with a media control, BDM, cytochalasin D, or both BDM and cytochalasin D. Closed arrowheads denote the leading edge 
localization of VASP. The percentage of cells with the phenotype pictured is noted for each treatment (n = 100 cells). Bars, 50 
um. 
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driven by retrograde flow [Figure 5A]. A linescan of the
leading edge shown in Figure 5A, plotted across time
shows the pattern and extent of loss of fluorescence signal
[Figure 5B]. Fluorescence levels decrease gradually with
little or no shift in the peak of fluorescence backward. By
two minutes, fluorescence levels at the leading edge are
equivalent to background. After washout of BDM, Arp3-
GFP localization returns in just over one minute. In all
cases, the loss of Arp3-GFP at the leading edge was seen
concomitantly with loss of ruffling and retraction of the
leading edge or as de-localization with slight retraction.
We did not see retrograde flow of the Arp3 signal in an
otherwise stable leading edge.
Discussion
BDM has been used to probe actin-dependent processes
on the assumption that it is a specific inhibitor of mys-
osins. BDM has recently been found not to inhibit the in
vitro  ATPase activity of human platelet nm-myosinII,
Acanthamoeba myosinIc, human myoIe, chicken myos-
inV, and porcine myosinVI, though it does inhibit rabbit
muscle myosinII [9,10]. Thus the literature's interpreta-
tions of BDM's effects are probably incorrect. Our results
suggest that the effects of BDM on actin-dependent proc-
esses such as cell motility and retrograde flow may result
from effects on proteins involved in actin polymerization
and the leading edge actin itself. It is not clear if these
effects on leading edge components are direct or indirect.
The loss of actin polymerization machinery, however, is a
previously un-described effect of BDM treatment and this
highlights the importance of defining the localization of
proteins involved in actin dynamics when leading edge
activity is disrupted.
BDM application leads to the loss of localization of lead-
ing edge components involved in actin nucleation. We
observe that within two minutes, application of BDM
leads to the de-localization of the leading edge compo-
nents – Arp3, VASP, and WAVE – and this is concurrent
with the loss of the actin network at the leading edge. Our
data suggest a mechanism of de-localization of Arp3 con-
sistent with dissociation or diffusion rather than retro-
grade flow. We cannot determine the causal relationship
between loss of leading edge components and loss of the
leading edge actin network itself. At the least, the two
occur simultaneously.
Interestingly,  Listeria  bacteria continue to move in the
presence of BDM, while the leading edge of the infected
cell stops ruffling. Both processes have been shown to
involve the Arp2/3 complex. That BDM inhibits one actin
dependent process but not the other, may be an
interesting difference in the location of polymerization
within the cell – actin polymerization at the leading edge
vs. the cell body, or a difference in the mechanism of actin
Figure 5
Arp3 de-localization consistent with dissociation 
from the actin network. (A) Time-lapse sequence of a BS-
C-1 cell expressing Arp3-GFP shows delocalization of Arp3 
within 2 minutes of BDM addition. (B) A linescan of the area 
marked at 0s (dotted line) plotted over time shows gradual 
loss of fluorescence with only slight retraction of the leading 
edge. Washout brings a return of fluorescence in ~1 minute. 
Bar, 10 um.BMC Cell Biology 2003, 4 http://www.biomedcentral.com/1471-2121/4/5
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polymerization – the leading edge vs. a Listeria bacterium.
BDM treatment thus seems to disrupt actin dynamics spe-
cific to the plasma membrane and this may provide a clue
to both the mechanism of BDM inhibition and the rela-
tionship of actin dynamics at the plasma membrane.
Current understanding of the retrograde flow of actin has
been influenced by the use of BDM in the sea urchin coe-
lomocyte and Aplysia bag cell neuron systems. Our data
are consistent with results in sea urchin coelomocytes
where BDM phenocopies the effect of cytochalasin D,
blocking retrograde flow at the leading edge with contin-
ued contraction of the actin network causing a clearing of
actin at the leading edge [11]. In the coelomyocte system,
de-localization of leading edge components by BDM
could account for the inhibition of actin polymerization
and clearing. In the Aplysia bag cell neuron, BDM applica-
tion leads to extension of filopodia and the growth cone
itself. Filopodial extension was interpreted as supporting
the clutch model, with myosins pulling filaments toward
the growth cone interior. When the myosin activity was
blocked with BDM treatment, continued actin polymeri-
zation, thought to occur as elongation of existing fila-
ments, lead to protrusion [12,27,28]. Our observation of
BDM activity suggests an alternative explanation. Perhaps
components required for nucleation are de-localized by
BDM allowing new polymerization to be re-directed to
filopodia, as filopodial extension is thought to be driven
by elongation and not nucleation [27]. The extension of
the growth cone itself could result from a similar
diversion of actin monomer from nucleation of new fila-
ments to extension of existing filaments. Treatment of
cells with BDM often leads to filopodia-like projections as
seen in Figure 1B and Figure 2B. Data from studies of in
vivo  and  in vitro filopodia formation suggest that they
develop as a reorganization of the dendritic network in
which they exist [29,30]. In the presence of proteins that
bundle and reorganize actin filaments into filopodial pre-
cursors, the de-localization of Arp2/3 and other leading
edge components may lead to the formation of filopodia,
which are then elongated as described above. Future stud-
ies will hopefully clarify the role of actin nucleation in the
Aplysia system or alternative mechanisms that would rec-
oncile the discrepancies between systems.
In all systems, a better understanding of how the leading
edge is constructed and maintained will require specific
and detailed descriptions of the activity and localization
of the proteins involved. Membrane ruffling, often used as
a measure of actin dynamics at the leading edge, is a very
crude readout. The sensitivity of the leading edge is dem-
onstrated by the observation that DMSO treatment at a
concentration of 1% causes temporary inhibition of ruf-
fling and concomitant Arp3 de-localization (Yarrow
unpublished results). Experimental approaches that may
help address how such a dynamic and sensitive structure
is established and maintained include combining inhibi-
tion of actin dynamics with the use of tools that affect
Arp2/3 or myosin activity or localization, in specific ways.
Though preliminary, we have seen that Arp3 is still local-
ized in the presence of latrunculin A and jasplakinolide,
and that this localization is lost with BDM treatment
unlike the combination of cytochalasin D and BDM (Yar-
row unpublished results). These results may in the end tell
us more about our understanding of what latrunculin A
and jasplakinolide do in vivo than the leading edge itself.
Regardless, this type of experiment awaits more specific
tools than BDM for follow up.
Though BDM has a relatively high effective concentration
(in the millimolar range), it was widely adopted by the
cell biology community because of its rapid and reversible
effect on cell behaviour. BDM has not been exhaustively
tested on all myosins, and a myosin target is not unrea-
sonable given findings in Acanthomoeba and S. cerviseae
though it does not inhibit Acanthamoeba myosinIc or
human myoIe in vitro [10,20,21,31]. Regardless, we and
others have shown that BDM is not the tool that should
be used to investigate these behaviours. The small mole-
cule approach continues to be an effective means to
develop tools for understanding cell biological process
when used and interpreted appropriately. One new com-
pound that will help clarify the role of nm-myosinII is
blebbistatin [32]. Other small molecules wait to be found
and experiments using them will continuously refine our
understanding of the leading edge and the mechanism of
action of these compounds.
Conclusions
De-localization of actin leading edge components by
BDM treatment is a newly described effect of this com-
pound. It may explain results previously ascribed to inhi-
bition of non-muscle myosinII by BDM, particularly in
retrograde flow studies. Though this effect of BDM is
intriguing, future studies that look at the establishment
and maintenance of the actin leading edge should use
more potent and specific inhibitors.
Methods
Platelet myosinII ATPase assay
The assay was performed using an EnzCheck phosphate
release assay (Molecular Probes). Platelet myosinII S1 was
diluted to 0.050 mg/ml in reaction buffer (0.2 M KCl, 10
mM Tris pH 7.0, 10 mM CaCl2, 2 mM MgCl2, 1 mM DTT,
0.2 mM 2-amino-6-mercapto-7-methyl purine riboside
(MESG) in the presence of 1 U purine nucleoside phos-
phorylase (PNP)). DMSO, 20 mM BDM, or 100 uM bleb-
bistatin was added to the reactions with a constant DMSO
concentration of 1%. ATP (100 uM) was added to initiate
the reaction and absorbance at 360 nm was read every ~6BMC Cell Biology 2003, 4 http://www.biomedcentral.com/1471-2121/4/5
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seconds for 20 minutes. BDM showed no effect on ATP
hydrolysis in the absence of myosin.
Tissue Culture
BS-C-1 cells and Swiss3T3 cells were acquired from the
ATCC (CCL-26, CCL-92). Cells were maintained in Dul-
becco's Modified Essential Medium with 4.5 g/L glucose,
10% fetal calf serum, and penicillin/streptomycin. Cells
were maintained at 37°C with 5% CO2.
Permeabilized cell assay
Permeabilized cell assays were performed in flow cham-
bers as previously described [22]. Swiss3T3 cells were
flowed into the chamber, the chamber inverted, and cells
allowed to spread for 30–45 minutes in a humidified
environment at 37°C, 5% CO2. The assay was performed
by adding 50 ul of the warmed sample solution to the
chamber while wicking with Whatman paper. Cells were
rinsed with PBS, treated with compounds or media for 1
min, permeabilized in the presence or absence of com-
pound for 3 min with permeabilization buffer (0.02 g/ml
of saponin, 20 mM HEPES (pH 7.5), 138 mM KCl, 4 mM
MgCl2, 3 mM ETGA, 1 mM DTT + protease inhibitors, 0.4
uM rhodamine actin, 1 mM ATP), and fixed in PBS + 3.7%
formaldehyde for 10 min.
Listeria infection
Listeria monocytogenes (strain 10403S) were grown over-
night in 3 mls of Brain Heart Infusion media at room
temp without shaking. BS-C-1 cells on 25 mm poly-L-
lysine (PLL) coverslips were rinsed with media containing
no antibiotics and placed in a 6 well plate. Listeria were
prepared by removing 1 ml of the overnight culture,
pelleting by a 1 min Eppendorf centrifuge spin, washing
the pellet twice with antibiotic-free media, and resuspend-
ing in 1 ml of media. 10 ul of Listeria were added to each
well and were allowed to infect for 1.5 hrs prior to the
addition of media containing 50 ug/ml Gentamicin. Cells
were imaged between 4 hrs and 12 hrs later.
Compound treatment for immunofluorescence
Cells were allowed to spread on 18 mm round PLL cover-
slips in a 12 well plate for 30–45 minutes or 2–4 hours
prior to treatment. BDM (Calbiochem 203984) stock
solution was made in media at 0.5 M and Cytochalasin D
(Sigma C8273) in DMSO at 20 mM. With the plate on a
37°C heat block, appropriately diluted concentrations of
each compound (15 or 20 mM BDM, 1 uM cytochalasin
D) were made in warmed media and added to cells after
removal of existing media. After 1 minute, the cells were
fixed for immunoflourescence as described below.
Immunofluorescence
Cells were fixed in a permeabilization/fixation buffer
(100 mM K-Pipes pH 6.8, 10 mM EGTA, 1 mM MgCL2,
0.2% TritonX-100, 3.7% formaldehyde) for 10 minutes.
For Arp3 immunofluorescence, cells were post-fixed in
methanol (-20°C) for 2 minutes. Coverslips were rinsed
with TBS containing 0.1% Triton X-100 (TBS-Tx) and
blocked in TBS-Tx with 2% BSA (AbDil) for 45 minutes.
Antibodies were diluted in AbDil and incubated for 45
minutes. Coverslips were rinsed in TBS-Tx and incubated
with fluorescently labeled secondary antibodies in TBS-Tx
for 45 minutes. Coverslips were rinsed and mounted in
90% glycerol with 0.5% p-phenylenediamine in 20 mM
Tris-pH 8.8.
Antibodies used: rabbit Arp3 antibodies (gift from C.
Egile using the same peptide as described [33]) used at
1:500 dilution, mouse actin antibodies (Santa Cruz SC-
8432) used at 1:10,000 dilution, rabbit VASP antibodies
(gift from F. Southwick) used at 1:100, rabbit WAVE1
antibodies (gift from S. Eden as described [26]) used at
1:100 and Alexa-dye labeled secondary antibodies, goat
anti-rabbit and goat anti-mouse (Molecular Probes).
GFP-Arp3 cell line
A stable BS-C-1 cell line was made by transfection of GFP-
Arp3 (gift from D. Schafer as described [34]) using
Fugene6 (Roche) and selection with 500 ug/ml Geneticin.
GFP expressing colonies were picked and expanded.
Live imaging of GFP-Arp3
GFP-Arp3 cells were split onto 25 mm PLL coated cover-
slips 4–6 hrs before imaging. Cells were transferred to Lie-
bovitz L-15 media with 10% fetal calf serum in a heated
(37°C) open-air chamber 15 minutes prior to imaging.
Images were captured on a Nikon TE300 inverted micro-
scope with appropriate neutral density filtering using an
Apo 100 × /1.4 NA oil emersion phase objective and cap-
tured on a CCD camera (Hammamatsu-OrcaER) using
Metamorph software. Images were taken every 15 s with
an exposure of 200–1000 ms.
Authors' contributions
JY prepared the manuscript and performed the time-lapse
microscopy,  Listeria, and myosin ATPase experiments.
Remaining experimentswere done in collaboration with
TL. RL and TM supervised this work and provided funding
and support. All authors read and approved the final
manuscript.
Acknowledgements
We thank Jeffrey Peterson with help and reagents with the pyrene actin 
assays, Aaron Straight for help and reagents with the ATPase assay, Cou-
mar Egile for Arp3 antibody, Sharon Eden for WAVE1 antibody, Dorothy 
Schafer for the Arp3-GFP plasmid, and Annette Pollington for the Listeria 
protocol. Mimi Shirasu-Hiza provided great help in writing, editing, and dis-
cussion and we'd also like to thank Jeffrey Peterson, Zach Perlman, Bill Brie-
her, Aaron Straight, and subgroup for helpful discussions.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cell Biology 2003, 4 http://www.biomedcentral.com/1471-2121/4/5
Page 9 of 9
(page number not for citation purposes)
This work was supported by the National Institutes of Health through grant 
GM48027 to TJM and GM057063 to RL. JCY was supported by a Howard 
Hughes pre-doctoral fellowship.
References
1. Peterson JR and Mitchison TJ: Small molecules, big impact. A
history of chemical inhibitors and the cytoskeleton Chem Biol
2002, 9:1275-1285.
2. Regnier M, Morris C and Homsher E: Regulation of the cross-
bridge transition from a weakly to strongly bound state in
skinned rabbit muscle fibers Am J Physiol 1995, 269:C1532-9.
3. McKillop DF, Fortune NS, Ranatunga KW and Geeves MA: The
influence of 2,3-butanedione 2-monoxime (BDM) on the
interaction between actin and myosin in solution and in
skinned muscle fibres J Muscle Res Cell Motil 1994, 15:309-318.
4. Cramer LP and Mitchison TJ: Myosin is involved in postmitotic
cell spreading J Cell Biol 1995, 131:179-189.
5. Olazabal IM, Caron E, May RC, Schilling K, Knecht DA and Machesky
LM: Rho-kinase and myosin-II control phagocytic cup forma-
tion during CR, but not FcgammaR, phagocytosis Curr Biol
2002, 12:1413-1418.
6. Keller H, Zadeh AD and Eggli P: Localised depletion of polymer-
ised actin at the front of Walker carcinosarcoma cells
increases the speed of locomotion Cell Motil Cytoskeleton 2002,
53:189-202.
7. Ruchhoeft ML and Harris WA: Myosin functions in Xenopus ret-
inal ganglion cell growth cone motility in vivo J Neurobiol 1997,
32:567-578.
8. Oliver T, Dembo M and Jacobson K: Separation of propulsive and
adhesive traction stresses in locomoting keratocytes J Cell Biol
1999, 145:589-604.
9. Cheung A, Dantzig JA, Hollingworth S, Baylor SM, Goldman YE,
Mitchison TJ and Straight AF: A small-molecule inhibitor of skel-
etal muscle myosin II Nat Cell Biol 2002, 4:83-88.
10. Ostap EM: 2,3-Butanedione monoxime (BDM) as a myosin
inhibitor J. Muscle Res. Cell Motil. 2002, 23:305-308.
11. Henson JH, Svitkina TM, Burns AR, Hughes HE, MacPartland KJ,
Nazarian R and Borisy GG: Two components of actin-based ret-
rograde flow in sea urchin coelomocytes Mol Biol Cell 1999,
10:4075-4090.
12. Lin CH, Espreafico EM, Mooseker MS and Forscher P: Myosin drives
retrograde F-actin flow in neuronal growth cones  Neuron
1996, 16:769-782.
13. Verkhovsky AB, Svitkina TM and Borisy GG: Network contraction
model for cell translocation and retrograde flow Biochem Soc
Symp 1999, 65:207-222.
14. Jay DG: The clutch hypothesis revisited: ascribing the roles of
actin-associated proteins in filopodial protrusion in the nerve
growth cone J Neurobiol 2000, 44:114-125.
15. Welch MD and Mullins RD: Cellular control of actin nucleation
Annu Rev Cell Dev Biol 2002, 18:247-288.
16. Nozumi M, Nakagawa H, Miki H, Takenawa T and Miyamoto S: Dif-
ferential localization of WAVE isoforms in filopodia and
lamellipodia of the neuronal growth cone  J Cell Sci 2003,
116:239-246.
17. Svitkina TM, Verkhovsky AB, McQuade KM and Borisy GG: Analysis
of the actin-myosin II system in fish epidermal keratocytes:
mechanism of cell body translocation J Cell Biol 1997, 139:397-
415.
18. Verkhovsky AB, Svitkina TM and Borisy GG: Self-polarization and
directional motility of cytoplasm Curr Biol 1999, 9:11-20.
19. Diefenbach TJ, Latham VM, Yimlamai D, Liu CA, Herman IM and Jay
DG: Myosin 1c and myosin IIB serve opposing roles in lamel-
lipodial dynamics of the neuronal growth cone J Cell Biol 2002,
158:1207-1217.
20. Lechler T, Shevchenko A, Shevchenko A and Li R: Direct involve-
ment of yeast type I myosins in Cdc42-dependent actin
polymerization J Cell Biol 2000, 148:363-373.
21. Evangelista M, Klebl BM, Tong AH, Webb BA, Leeuw T, Leberer E,
Whiteway M, Thomas DY and Boone C: A role for myosin-I in
actin assembly through interactions with Vrp1p, Bee1p, and
the Arp2/3 complex J Cell Biol 2000, 148:353-362.
22. Symons MH and Mitchison TJ: Control of actin polymerization in
live and permeabilized fibroblasts J Cell Biol 1991, 114:503-513.
23. Urbanik E and Ware BR: Actin filament capping and cleaving
activity of cytochalasins B, D, E, and H Arch Biochem Biophys
1989, 269:181-187.
24. Li R, Zheng Y and Drubin DG: Regulation of cortical actin
cytoskeleton assembly during polarized cell growth in bud-
ding yeast J Cell Biol 1995, 128:599-615.
25. Reinhard Matthias, Jarchau Thomas and Walter Ulrich: Actin-based
motility: stop and go with Ena/VASP proteins Trends in Bio-
chemical Sciences 2001, 26:243-249.
26. Eden S, Rohatgi R, Podtelejnikov AV, Mann M and Kirschner MW:
Mechanism of regulation of WAVE1-induced actin nuclea-
tion by Rac1 and Nck Nature 2002, 418:790-793.
27. Mallavarapu A and Mitchison T: Regulated actin cytoskeleton
assembly at filopodium tips controls their extension and
retraction J Cell Biol 1999, 146:1097-1106.
28. Suter DM, Errante LD, Belotserkovsky V and Forscher P: The Ig
superfamily cell adhesion molecule, apCAM, mediates
growth cone steering by substrate-cytoskeletal coupling J Cell
Biol 1998, 141:227-240.
29. Svitkina TM, Bulanova EA, Chaga OY, Vignjevic DM, Kojima S, Vasiliev
JM and Borisy GG: Mechanism of filopodia initiation by reor-
ganization of a dendritic network J Cell Biol 2003, 160:409-421.
30. Vignjevic D, Yarar D, Welch MD, Peloquin J, Svitkina T and Borisy
GG: Formation of filopodia-like bundles in vitro from a den-
dritic network J Cell Biol 2003, 160:951-962.
31. Jung G, Remmert K, Wu X, Volosky JM and Hammer J. A., 3rd: The
Dictyostelium CARMIL protein links capping protein and the
Arp2/3 complex to type I myosins through their SH3
domains J Cell Biol 2001, 153:1479-1497.
32. Straight AF, Cheung A, Limouze J, Chen I, Westwood NJ, Sellers JR
and Mitchison TJ: Dissecting Temporal and Spatial Control of
Cytokinesis with a Myosin II Inhibitor Science 2003, 299:1743-
1747.
33. Welch MD, DePace AH, Verma S, Iwamatsu A and Mitchison TJ: The
human Arp2/3 complex is composed of evolutionarily con-
served subunits and is localized to cellular regions of
dynamic actin filament assembly J Cell Biol 1997, 138:375-384.
34. Schafer DA, Welch MD, Machesky LM, Bridgman PC, Meyer SM and
Cooper JA: Visualization and molecular analysis of actin
assembly in living cells J Cell Biol 1998, 143:1919-1930.